Clearbridge BioMedics (CBB) is a spin-off from the National University of Singapore (NUS) and is also the first incubatee of Clearbridge Accelerator, a Singapore Government (National Research Foundation) backed high-technology incubator. CBB is also a successful recipient of SPRING Singapore’s Technology Enterprise Commercialisation Scheme (TECS) Proof-of-Value (POV) Grant.
Leveraging on a patent-pending microfluidic biochip invention, the ClearCell™ System, comprising the ClearCell™ Unit and a range of CTChips®, is one of the world‘s first cell isolation systems that is able to detect and isolate wholly intact Circulating Tumour Cells (CTCs) from blood.